Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation

AbbVie is launching Humira on the TrumpRx platform with an 86% discount under a pricing agreement with the White House. The ...

Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?

Pfizer PFE and AbbVie ABBV are leading U.S. drugmakers with strong positions across multiple therapeutic areas. Oncology ...
Zacks Investment Research on MSN

How will Skyrizi and Rinvoq shape AbbVie's Q1 immunology sales?

AbbVie ABBV is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology ...

Alvotech Earnings Call: Growth Momentum Meets FDA Risk

Alvotech reported 2025 revenues of $593 million, up about 21% year over year, as its biosimilar portfolio and partner network continued to scale globally. Adjusted EBITDA climbed 27% to $137 million, ...
Healio

Rapid increase in Humira biosimilar orders after CVS formulary change not sustained

Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...